Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Bone

Use of bisphosphonates in children—proceed with caution

A clinical review of studies on bisphosphonate therapy for pediatric osteoporosis has revealed that they increase BMD, but whether they also improve fracture rates or functions of daily life is unclear. Can the findings of this clinical review help inform clinicians whether, when and how to use these agents in children?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Bachrach, L. K. & Ward, L. M. Clinical review: bisphosphonate use in childhood osteoporosis. J. Clin. Endocrinol. Metab. 94, 400–409 (2009).

    CAS  Article  Google Scholar 

  2. 2

    Letocha, A. D. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J. Bone Miner. Res. 20, 977–986 (2005).

    CAS  Article  Google Scholar 

  3. 3

    Marini, J. C. Should children with osteogenesis imperfecta be treated with bisphosphonates? Nat. Clin. Pract. Endocrinol. Metab. 2, 14–15 (2006).

    Article  Google Scholar 

  4. 4

    Rauch, F., Travers, R. & Glorieux, F. H. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J. Clin. Endocrinol. Metab. 91, 511–616 (2006).

    CAS  Article  Google Scholar 

  5. 5

    Uveges, T. E. et al. Alendronate treatment of Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J. Bone Miner. Res. [doi:10.1359/jbmr.081238] (2008).

  6. 6

    Li, J. S. et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297, 480–488 (2007).

    CAS  Article  Google Scholar 

  7. 7

    Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H. & Mumm, S. Bisphosphonate-induced osteopetrosis. N. Engl. J. Med. 349, 457–463 (2003).

    CAS  Article  Google Scholar 

  8. 8

    Whyte, M. P. et al. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J. Bone Miner. Res. 23, 1698–1707 (2008).

    Article  Google Scholar 

  9. 9

    Allen, M. R. & Burr, D. B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J. Bone Miner. Res. 22, 1759–1765 (2007).

    CAS  Article  Google Scholar 

  10. 10

    Weinstein, R. S., Robertson, P. K. & Manolagas, S. C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53–62 (2009).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Joan C. Marini.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Marini, J. Use of bisphosphonates in children—proceed with caution. Nat Rev Endocrinol 5, 241–243 (2009). https://doi.org/10.1038/nrendo.2009.58

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing